Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24555862 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14791220 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1717631 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14791219 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL6673714 | 1.00 | USP30 (0.55) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL13177349 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL853539 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL1055082 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL14037432 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 | |
| SCHEMBL853540 | 0.92 | USP30 (0.62) | USP30L3MBTL1ATMALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3865484-B1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2023-11-08 | — | — | EP | disclosed |
| EP-3630772-B1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | IMARA INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | disclosed |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11608342-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | H. LUNDBECK A/S (DK) | 2023-03-21 | — | — | US | disclosed |
| CN-115746003-A | Methods of making and using PDE9inhibitors | 伊马拉公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-2152712-B1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER (US) | 2012-01-11 | — | — | EP | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2152712-A1 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| WO-2008139293-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1112253-B1 | BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6245801-B1 | ANTIEPILEPIC AGENTS; BRAIN DISORDERS; PSYCHOLOGICLA DISORDERS | WARNER-LAMBERT COMPANY | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608342-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | PDE9A, PDE5A, PDE3A | USP30 2996/4885L3MBTL1 4673/4885ATM 3119/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | USP30 3468/4885L3MBTL1 3371/4885ATM 1477/4885 |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE4B, PDE12 | USP30 2800/4885L3MBTL1 1364/4885ATM 1890/4885 |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | USP30 2996/4885L3MBTL1 4673/4885ATM 3119/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885L3MBTL1 1110/4885ATM 3213/4885 |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | USP30 1641/4885L3MBTL1 4050/4885ATM 833/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | USP30 19/4885L3MBTL1 400/4885ATM 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.